Compare Vanguard International High Dividend Yield ETF (VYMI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard International High Dividend Yield ETF vs Zoetis Inc — how do they compare? Vanguard International High Dividend Yield ETF trades at $105.38, while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc pays a 2.89% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VYMI | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $107.13 | $150.61 |
52-Week Low | $82.92 | $71.91 |
Market Cap | — | $30.29B |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $106.20, down 0.78% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF has gained attention for its international high-dividend yield strategy, recently hitting a 52-week high near current levels. Recent news highlights its outperformance versus domestic dividend ETFs and growing institutional interest.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's strong dividend growth. Key risks include currency fluctuations and global economic volatility. With technical support at $105-106 and resistance at $107-108, the ETF offers income-focused exposure to international equities.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
